Study the effect of a drug depakene (Valproic acid) in the serum levels of immune proteins in albino male rats.
Article Sidebar
Main Article Content
Abstract
This study aimed to investigate the effect of administration of depakene (valproic acid)(VPA) (15 mg/Kg of body weight, orally) on serum protein levels, including immune proteins, because its functions and the importance of these proteins in the body and they are overlapping, and that was by measured protein levels before and after treatment as concentrations of total protein (Tp), albumin and globulin in normal male rats and in rats that treated with VPA drug along the period of experiment (30) days. The results showed a significant decrease (P<0.05) in concentrations of total protein and albumin in comparison with normal control group, whereas did not observe significant differences (P<0.05) in globulin concentration compared with normal control group, despite of, there was a little decrease in globulin concentration in rats group that administrated the drug under study but non-significant. It could be concluded of the present study that the VPA drug have an greater side effects on concentration and function of proteins in serum, and subsequently, may extending these effects to comprise its effect on the immunity, osmotic pressure, blood volume, nutrients exchange between the blood and tissues, glomerular infiltration rate, transport many of materials and hormones, and several of physiological and biochemical functions which correlated with the serum proteins
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1-Porter, R. J. and Meldrum, B. S. (1998). Antiepileptic drugs. In: Katzung BG. Basic and Clinical Pharmacology. 7th ed., Appleton and Lange, San Francisco, Pp: 386-408.
2- Bolanos, A. R., Sarkisian, M., Yang, Y., Hori, A., Helmers, S. L., Mikati, M., Tandon, P., Stafstrom, C. E. and Holmes, G. L. (1998). Comparison of valproate and phenobarbital treatment after status epilepticus in rats. Neurology; 51: 41-48.
3-Duncan, S. (2007). Teratogenesis of sodium valproate. Current Opinion in Neurology; 20: 175-180.
4- Perucca, E. (2002). Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs; 16(10): 695-714.
5- Sathiyapalan, A. (2013). Effects of valproic acid on expression of the melato-nin receptors MT1 and MT2, and neuropathic factors BDNF and GDNF in vivo. McMaster University, Theses in Neuroscience, Hamilton, Ontario.
6- Vreugdenhil, M. and Wadman, W. J. (1999). Modulation of sodium currents in rat CA1 neurons by carbamazepine and valproate after kindling epileptogenesis. Epilepsia; 40: 1512-1522.
7- Chang, P. (2009). Valproate and 4-methyloctanoic acid, an analogue of valpro-ate, in animal models of epilepsy. Department of Clinical and Experimental Epilepsy Institute of Neurology, Thesis. Pp:65-71.
8- Chateauvieux, S., Morceau, F., Dicato, M., and Diederich, M. (2010). Molec-ular and therapeutic potential and toxicity of valproic acid. Journal of Biomedicine & Biotechnology; 1-5.
9- Almutawaa, W. S. (2013). Inducation of neuropathic and differentition genes in neural stem cells by valproic acid. McMaster University, Theses in Neuroscience, Hamilton, Ontario; 9-12.
10- Thapa, B. R. and Walia, A. (2007). Liver Function Tests and their Inter-pretation. Indian Journal of Pediatrics; 74: 663-670.
11- Činčárová, L., Zdráhal, Z. and Fajkus, J. (2013). New perspectives of valproic acid in clinical practice. Expert Opinion on Investigational Drugs; 22(12): 1535-1547.
12- Barron, M. E., Wilkes, M. M. and Navickis, R. J. (2004). A systematic review of the comparative safety of colloids. Arch Surg;139: 552-563.
13-Banh, L. (2006). Serum Proteins as Markers of Nutrition: What Are We Treat-ing?. GASTROENTEROLOGY; 43: 46-60.
14- Daniel, S. P. and Marshall, M. K. (1999). Evaluation of the liver: laboratory tests. Schiff’s diseases of the liver, 8th ed. USA; JB Lippincott publications, Pp:205-239.
15- Craig, W. Y., Ledue, T. B. and Ritchie, R. F. (2000). Plasma proteins: clinical utility and interpretation. Foundation for Blood Research, Pp:3-144. www.fbr.org
16- WHO. (2011). Serum retinol concentrations for determining the prevalence of vitamin A deficiency in populations. Vitamin and Mineral Nutrition Information System. Geneva, Pp:1-4. http://www.who.int/vmnis/indica-tors/retinol.pdf
17- Marshall, W. (2012). Total protein (serum, plasma). Association for Clinical Biochemistry, Pp:1-5. 18- Al-Janabi, Q. A. (2008). Study the effect of aqueous extract of grape seeds in oxidative stress induced by hydrogen peroxide in male rats. M.Sc. College of Education, University of Tikrit.
19- Tietz, N. W. (1995). Clinical Guide to Laboratory Tests. 3rded. W.B. Saunders Company, Philadelphia, USA. Pp: 266-273.
20- Doumas, B. T., Waston, W. A. and Bigg, H. G. (1971). Albumin standards and the measurement of serum albumin with BCG. Clin Chim Acta; 31: 87-96.
21- Tietz, N. W. (1987). Fundamentals of clinical chemistry. W.B.Saunders Co, Philadelphia, USA. Pp: 940.
22- Sharma, S., et al. (2008). Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol; 294: 46-56.
23- Bonnefont, J. P., Bastin, J., Behin, A. and Djouadi, F. (2009). Bezafibrate for treatment of an inborn mitochondrial ß-oxidation defect. N Engl J Med; 360: 838-840.
24- Thornalley, P. J. (2006). Protein oxidation marker residues and oxidized amino acids in disease: the damage and the debris of protein oxidation . In Protein Oxidation and Disease , Pandalai SG , Pietzsch J , eds. Kerala, India : Research Signpost , Pp: 143-178 .
25- Kuhlmann, M.K., Burkhardt, G. and Kohler, H. (1997). Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol. Dial. Transplant; 12: 2478-2480.
26- Vorum, H., Gram, L. and Honore, B. (1993). Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity. Epilepsy Res; 16: 55-64.
27- Halliwell, B. and Gutteridge, J. M. (1999). Free Radical in Biology and Medicine. 3rd ed. Oxford, Oxford University Press, Pp:146-163, 399-430.
28- George, B. O. and Osharechiren, O. I. (2009). Oxidative stress and antioxidant status in sportsmen
two hours after strenuous exercise and in sedentary control subjects. African J Biotechnol; 8(3): 480-483.
29- Syed, N. A. and Zaeem, A. S. (2005). Antiepileptic drugs and liver disease. Seizure; 15: 156-164.
30- Fuhrman, M. P., Charney, P. and Mueller, C. M. (2004). Hepatic proteins and nutrition assessment. J Am Diet Assoc; 104: 1258-1264.
31- Soeters, P. B. and Schols, A. M. (2009). Advances in understanding and assessing malnutrition. Curr Opin Clin Nutr Metab Care; 12: 487-494.